CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum
Nivolumab lengthened survival compared with standard single-agent chemotherapy in head and neck cancer that had progressed within six months of platinum treatment, the first immunotherapy to improve survival in the disease.
Overview
Phase 3 trial of 361 patients with recurrent or metastatic head and neck squamous cell carcinoma progressing within six months of platinum-based therapy, randomised 2:1 to nivolumab or investigator's choice of methotrexate, docetaxel or cetuximab.
Median overall survival was 7.5 versus 5.1 months (hazard ratio 0.70) and one-year survival 36.0 versus 16.6 percent, with fewer grade 3 to 4 adverse events (13.1 versus 35.1 percent) and better quality of life.
- Median overall survival 7.5 vs 5.1 months; hazard ratio 0.70.
- One-year overall survival 36.0 percent vs 16.6 percent.
PD-1 blockade after platinum became standard, and the trial opened the way for first-line pembrolizumab in KEYNOTE-048.
- Response rate was low (13.3 percent); benefit accrues to a minority of durable responders.
Similar pages
not linked directly; found by shared links- Key paperHuman papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)
Shares Oropharyngeal cancer (tonsil and base of tongue), New England Journal of Medicine.
- Key paperEXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer
Shares Recurrent or metastatic head and neck squamous cell carcinoma, New England Journal of Medicine.
- Key paperCheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer
Shares New England Journal of Medicine, Nivolumab.
- Key paperCheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma
Shares New England Journal of Medicine, Nivolumab.
- TrialBonner trial (cetuximab plus radiotherapy)
Shares Oropharyngeal cancer (tonsil and base of tongue), Recurrent or metastatic head and neck squamous cell carcinoma.
- Key paperCheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Shares New England Journal of Medicine, Nivolumab.
- Key paperCheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Shares New England Journal of Medicine, Nivolumab.
- TreatmentCelecoxib
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Nivolumab.